Kidney Cancer Clinical Trial

Axitinib Therapy Management Study

Summary

The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI

View Full Description

Full Description

not mandatory

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmed diagnosis of aRCC (Stage III, Stage IV (M0) or Stage IV (M1)) at any point
Age 18 years or older at the time of aRCC diagnosis
Received a qualifying IO-containing combination (nivolumab and ipilimumab, axitinib and pembrolizumab, or axitinib and avelumab) in the first regimen after aRCC diagnosis or axitinib monotherapy in any line

Exclusion Criteria:

none

Study is for people with:

Kidney Cancer

Study ID:

NCT04555603

Recruitment Status:

Withdrawn

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Pfizer Inc.
New York New York, 10017, United States

How clear is this clinincal trial information?

Study is for people with:

Kidney Cancer

Study ID:

NCT04555603

Recruitment Status:

Withdrawn

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider